

## Press Release

6 January 2021

### FOR IMMEDIATE RELEASE

#### Good news on Ivermectin for treatment of Covid-19

New British research has examined and pooled data from a wide range of international studies – including Argentina, Bangladesh, Iran, Pakistan, Spain, Egypt, India and the US – and found that the anti-parasitic medicine Ivermectin not only reduces deaths from Covid-19, but can be used to protect doctors and nurses – as well as others who have had ‘contacts’ with ill people – from getting the infection.

The report was published last week by an independent UK-based medical research company, the Evidence-Based Medicine Consultancy Ltd (E-BMC).

The research was conducted to support the recent findings of Dr Pierre Kory and clinical experts of the Front Line Covid-19 Critical Care Alliance (FLCCC) in the US.

Doctors around the world are now working together to raise awareness of this life-saving medicine which probably reduces the risk of a person dying from Covid-19 by between 65% and 95%.

In addition, the researchers believe that ivermectin should be offered as a prophylactic measure to health care workers as soon as possible because the analysis shows that ivermectin substantially reduces Covid-19 infections in these at risk groups.

The conclusions of the new global research are so clear that it is believed Ivermectin should be viewed as an essential drug to reduce the severity of illness and fatalities caused by the Covid-19 virus.

In most studies included in the review, the doses of Ivermectin given were similar to those given for common parasitic infections in humans (e.g. 0.2mg/kg orally, equivalent to a 12mg tablet for a 60 kg adult).

Commenting on the research, Dr Tess Lawrie of the E-BMC, said, “This is really good news. Ivermectin will have a significant impact on the battle against COVID-19.

“It also offers great hope for the better protection of our doctors and nurses who are on the front lines of this terrible crisis, as well as the protection of those who have had ‘contacts’ with sick people.

“Ivermectin is a well-known, safe and inexpensive medicine that is currently unlicensed in the UK for human use.

“This research is the integration of global efforts by clinicians, researchers, and study participants to make a difference in the fight against Covid-19. We owe a debt of thanks to them all.

“I hope that policymakers now respond to this information with the required urgency to save lives and protect our health care workers.”

###

## NOTES TO EDITORS

1. Dr Lawrie has written to Mr Hancock and Mr Ashworth but has not yet had a reply. Today she recorded a video letter in an urgent attempt to reach the Prime minister. This letter has been posted on [www.e-bmc.co.uk](http://www.e-bmc.co.uk).
2. The report can also be found on [www.e-bmc.co.uk](http://www.e-bmc.co.uk)
3. Health care professionals may wish to refer to the clinical guidance on Ivermectin use at the Front Line COVID-19 Critical Care Alliance (<https://covid19criticalcare.com/>).
4. Ivermectin is used in the treatment of various parasitic diseases such as river blindness, round worm, lice and scabies. This safe and inexpensive drug is on the Essential Medicines list of the World Health Organization (WHO) and is also used by veterinarians to treat parasitic infections in animals.
5. Ivermectin was originally derived from soil bacteria in Japan by Dr Satoshi Omura (Japan) and Dr William Campbell (USA) who were awarded a Nobel prize for its discovery in 2015.
6. The FLCCC review on which the EBMC rapid review is based can be found at <https://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Ivermectin-in-the-prophylaxis-and-treatment-of-COVID-19.pdf>
7. The scientist in charge of the meta-analysis, Dr Tess Lawrie has no commercial interests in the drug Ivermectin and nor does E-BMC Ltd.
8. Dr Tess Lawrie has no connection to the FLCCC expert group at <https://covid19criticalcare.com/>
9. Tess Lawrie has shared the data files used in the E-BMC report with Dr Andrew Hill of Liverpool University. <https://www.youtube.com/watch?v=yOAh7GtvcOs>

## PRESS RELEASE CONTACTS

Mark Lawrie  
07780 868283  
[mark@e-bmc.co.uk](mailto:mark@e-bmc.co.uk)  
[www.e-bmc.co.uk](http://www.e-bmc.co.uk)